Literature DB >> 27779712

PA-MSHA inhibits proliferation and induces apoptosis in human non-small cell lung cancer cell lines with different genotypes.

Xinmin Zhao1, Xianghua Wu1, Wen Yu2, Xuwei Cai2, Qi Liu2, Xiaolong Fu2, Zhebin Liu2, Dali Hu3, Shiyun Pan3, Qiling Huang3.   

Abstract

The present study examined the potential of Pseudomonas aeruginosa-mannose sensitive hemagglutinin (PA-MSHA) to inhibit proliferation and induce apoptosis in non‑small‑cell lung cancer (NSCLC) cell lines. It also investigated its mechanisms of action in different genotypes of human NSCLC. A total of three NSCLC cell lines, PC‑9, A549, and NCI‑H1975, were treated with PA‑MSHA at different concentrations. The anti‑proliferative effect of PA‑MSHA was evaluated using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. Cell cycle distribution and apoptosis induced by the treatment were measured by flow cytometry (FCM) with Annexin V/propidium iodide staining. Western blotting was conducted to determine the expression level of apoptosis‑associated proteins. PA‑MSHA was demonstrated to exert a time‑ and concentration‑dependent cytotoxic effect in PC‑9, A549, and NCI‑H1975 cells. The FCM indicated that all the different concentrations of PA‑MSHA used in the present study induce apoptosis and cell cycle arrest of NSCLC cells. Treatment with PA‑MSHA may exert anti‑proliferative effects on NSCLC cells by affecting regulation of the cell cycle and inducing apoptosis that is mediated in part by an intrinsic apoptosis signaling pathway. These data suggest that PA‑MSHA has the potential to inhibit proliferation and induce apoptosis in NSCLC cells. Furthermore, these data provide mechanistic details for the potential application of PA‑MSHA‑based therapeutic strategies for the treatment of different NSCLC genotypes. This present study suggests potential novel strategies to maximize effective therapeutic strategies targeting anti‑epidermal growth factor receptor for future clinical trials.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27779712     DOI: 10.3892/mmr.2016.5869

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  3 in total

Review 1.  Pseudomonas aeruginosa in Cancer Therapy: Current Knowledge, Challenges and Future Perspectives.

Authors:  Zheng Pang; Meng-Di Gu; Tong Tang
Journal:  Front Oncol       Date:  2022-04-28       Impact factor: 5.738

2.  Intratumoral Microbiome of Human Primary Liver Cancer.

Authors:  Dingding Qu; Yi Wang; Qingxin Xia; Jing Chang; Xiangnan Jiang; He Zhang
Journal:  Hepatol Commun       Date:  2022-02-22

3.  Topical Application of Pseudomonas aeruginosa-Mannose Sensitive Hemagglutinin (PA-MSHA) for Refractory Lymphatic Leakage Following Lymphadenectomy in Patients with Gynecological Malignancies.

Authors:  Rong Zhou; Jie Xu; Jingke He; Yao Gong; Hui Wang; Hua Linghu
Journal:  Cancer Manag Res       Date:  2021-06-21       Impact factor: 3.989

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.